[A21-79] Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 19.11.2021
Commission awarded on 01.07.2021 by the Federal Joint Committee (G-BA).
Treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-33||Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A18-54||Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G13-01||Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|A21-134||Bosutinib (chronic myelogenous leukaemia) - Addendum to Commission A21-79||Commission completed|